Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab as second-line therapy in elderly patients with advanced esophageal squamous cell cancer
2017-002056-86Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by AIO-Studien. Primary endpoint: Overall survival. Started Oct 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2017-002056-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002056-86.